JP2024533121A5 - - Google Patents
Info
- Publication number
- JP2024533121A5 JP2024533121A5 JP2024513749A JP2024513749A JP2024533121A5 JP 2024533121 A5 JP2024533121 A5 JP 2024533121A5 JP 2024513749 A JP2024513749 A JP 2024513749A JP 2024513749 A JP2024513749 A JP 2024513749A JP 2024533121 A5 JP2024533121 A5 JP 2024533121A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition
- cells
- cancer
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239797P | 2021-09-01 | 2021-09-01 | |
| US63/239,797 | 2021-09-01 | ||
| PCT/US2022/075678 WO2023034808A1 (en) | 2021-09-01 | 2022-08-30 | Mixed lineage kinase inhibitors and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533121A JP2024533121A (ja) | 2024-09-12 |
| JP2024533121A5 true JP2024533121A5 (enExample) | 2025-09-03 |
Family
ID=83447780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513749A Pending JP2024533121A (ja) | 2021-09-01 | 2022-08-30 | 混合系統キナーゼ阻害薬および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250032489A1 (enExample) |
| EP (1) | EP4395899A1 (enExample) |
| JP (1) | JP2024533121A (enExample) |
| KR (1) | KR20240055041A (enExample) |
| CN (1) | CN118251387A (enExample) |
| AU (1) | AU2022340743A1 (enExample) |
| CA (1) | CA3229861A1 (enExample) |
| WO (1) | WO2023034808A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024238570A1 (en) * | 2023-05-15 | 2024-11-21 | Aleksia Therapeutics, Inc. | Cdk2 inhibitor pyrazolopyrimidine compounds |
| WO2025188848A1 (en) * | 2024-03-06 | 2025-09-12 | Uereka Biosciences, Inc. | Lzk inhibitors |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO2012020786A1 (ja) * | 2010-08-11 | 2012-02-16 | 日本新薬株式会社 | 医薬組成物 |
| EP2441755A1 (en) * | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
| JP6267193B2 (ja) * | 2012-05-22 | 2018-01-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ジピリジルアミン類及びそれらの使用 |
| MX2015009270A (es) * | 2013-01-18 | 2015-10-30 | Hoffmann La Roche | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). |
| TWI710558B (zh) * | 2013-05-01 | 2020-11-21 | 瑞士商赫孚孟拉羅股份公司 | 二雜芳基化合物及其用途 |
| RU2015147601A (ru) * | 2013-05-01 | 2017-06-05 | Ф. Хоффманн-Ля Рош Аг | С-связанные гетероциклоалкилзамещенные пиримидины и их применения |
| MX2016008110A (es) * | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| MX2019002444A (es) * | 2016-08-29 | 2019-09-02 | Univ Texas | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. |
| CA3045947A1 (en) * | 2016-12-08 | 2018-06-14 | Michael J. Soth | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease |
-
2022
- 2022-08-30 WO PCT/US2022/075678 patent/WO2023034808A1/en not_active Ceased
- 2022-08-30 KR KR1020247010519A patent/KR20240055041A/ko active Pending
- 2022-08-30 CA CA3229861A patent/CA3229861A1/en active Pending
- 2022-08-30 AU AU2022340743A patent/AU2022340743A1/en active Pending
- 2022-08-30 CN CN202280073643.1A patent/CN118251387A/zh active Pending
- 2022-08-30 EP EP22777538.4A patent/EP4395899A1/en active Pending
- 2022-08-30 JP JP2024513749A patent/JP2024533121A/ja active Pending
- 2022-08-30 US US18/688,126 patent/US20250032489A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105473581B (zh) | 作为溴结构域抑制剂的新取代的双环化合物 | |
| CN105407888B (zh) | 新双环溴结构域抑制剂 | |
| JP2011509309A5 (enExample) | ||
| CN111170991B (zh) | 抗增殖化合物及其合成方法 | |
| CN104302638B (zh) | 用于抑制abl1、abl2和bcr-abl1的活性的苯甲酰胺衍生物 | |
| CN106660974B (zh) | 含氨磺酰基的1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| JP2020504766A (ja) | 免疫調節剤として有用な化合物 | |
| DK2197878T3 (en) | FORMATIONS OF kinase inhibitors AND USE THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES RELATED TO kinases | |
| CN103402519B (zh) | 肿瘤治疗剂 | |
| CN108289960B (zh) | Ep4受体拮抗剂用于治疗nash相关肝癌的用途 | |
| KR101921764B1 (ko) | 피라졸로-퀴놀린 | |
| CN109748915A (zh) | 流感病毒复制抑制剂及其使用方法和用途 | |
| JP2023539754A5 (enExample) | ||
| JP2022119852A5 (enExample) | ||
| TW529950B (en) | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | |
| JP5511689B2 (ja) | ウイルス性疾患および／または癌腫の予防および／または治療のためのｓｇｋ１阻害剤 | |
| CN114516857A (zh) | Hpk1抑制剂及其用途 | |
| TW201927787A (zh) | 吡咯並三嗪化合物及抑制ｔａｍ激酶之方法 | |
| KR101632326B1 (ko) | 니트릴 유도체 | |
| JP2022533020A (ja) | がん免疫療法アジュバント | |
| JP3208437B2 (ja) | 癌転移抑制剤 | |
| JP2025508016A (ja) | Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法 | |
| WO2020006724A1 (zh) | 一种靶向降解fak蛋白的化合物及其应用 | |
| WO2022143610A1 (zh) | 新型酰胺吡咯类化合物及其在药物中的应用 | |
| JP2010529032A (ja) | 治療方法 |